Not Signed In - QuatRx Pharmaceuticals Reports Positive Results From A Phase 2 Trial Of Fispemifene
Tue, 09 Jan 2007 08:00 AM EST
... QuatRx Pharmaceuticals today announced positive results from its Phase 2 clinical study of fispemifene in men with low testosterone levels. Fispemifene is a new, selective estrogen receptor antagonist that is being developed as an oral treatment for testosterone deficiency and associated disorders in men. [click link for full article] ...
Related Topics
- Clinical Trials
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Tb
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Well Baby Reports
- Tuberculosis Surveillance Reports
- Chronic Disease Notes And Reports
- Chronic Disease At A Glance Reports
- Vaccine Safety and Adverse Event Reports
- Sexually Transmitted Disease Surveillance Reports
- HLA-B27
- Triple Screen
- TB Skin Test
- Desipramine
- Trastuzumab
- HIV/AIDS Surveillance Reports
- National Vital Statistics Reports
- Eletriptan
- Tarceva
email this page
print this page
bookmark this page
feedback on this page
